15th Annual International Lung Cancer Congress®
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 20.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, Clovis Oncology, Genentech, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
15th Annual International Lung Cancer Congress®
OverviewThe International Lung Cancer Congress® provides current, practical information on the management of lung cancer, as well as a look at the novel agents and strategies that will shape the future of lung cancer therapy. Leading international and national faculty will address critical topics in lung cancer staging, personalized therapy, and the latest clinical data impacting the treatment of lung cancer. Cutting-edge lectures, panel discussions, multidisciplinary tumor boards, and interactive question-and-answer sessions will provide a unique opportunity for participants to engage with faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management. The meeting also includes a recurring session that highlights clinical research activity of Cooperative Groups in the United States, Europe, and Asia.
Target AudienceThis educational activity is directed toward medical, surgical and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers and other healthcare professionals interested in the treatment of lung cancer are also invited to attend.
- Compare and contrast the clinical outcomes of first- and second-generation EGFR inhibitors and ALK inhibitors for NSCLC patients across all lines of therapy
- Summarize guidelines from CAP, ASCO, and NCCN regarding both mutational analysis and use of molecularly targeted agents for patients with NSCLC
- Evaluate data on new agents and approaches in development for lung cancer
- Review recent data on immune-checkpoint inhibition with anti-PD-1, anti-PD-L1, and anti-CTLA-4 blockade
- Assess how emerging data on the use of molecularly targeted agents can be used to improve the treatment of patients with NSCLC
- Describe the NSCLC maintenance therapy standards of care and current options for improved patient outcomes applying multi-targeted antifolate, anti-angiogenesis and anti-EGFR strategies
- Summarize the factors to be considered when making treatment sequencing decisions, including efficacy of a drug at different stages, prior therapies, existing comorbidities, disease characteristics, and the need for molecular testing
The International Lung Cancer Congress® is endorsed by:
IASLC is the only global organization dedicated to the study of lung cancer. Founded in 1972, the association's membership includes more than 3,000 lung cancer specialists in 80 countries. IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public.
BJALCF is the first international collaborative entity of its kind, raising over $6 million for Lung Cancer research. BJALCF's focus is on projects promising progress through early detection, genetic testing, and drug discovery with patient-focused outcomes. Their ultimate goal is to increase the low survival rate of lung cancer by becoming the largest source of non-profit funding dedicated to turning lung cancer into a manageable chronic disease. Since 2008, BJALCF has sponsored a key-note address and provided overall support of the International Lung Cancer Congress.
Disclosure Policy and Resolution of Conflicts of Interest (COI)It is the policy of PER® to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with the ACCME Standards for Commercial SupportSM, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to the start of each activity. Participants are notified prior to the activity of the presence or absence of relevant financial relationships between faculty and commercial interests. Information disclosed includes the name of the faculty, nature of the relevant financial relationship (eg, member of speaker’s bureau, grant/research support, or consulting arrangement), and the name of the company/organization with which the relationship exists. Additionally, prior to the start of each activity PER® discloses the source of commercial support to the participants.
Faculty and Staff DisclosuresThe following individuals have no relevant financial relationships with commercial interests to disclose:
Walter John Curran, Jr., MD; Emily Duffield, APRN; Laurie Gaspar, MD; Daniel Lieber, MD; Philip C. Mack, PhD; James L. Mulshine, MD; Harvey I. Pass, MD; Stephen G. Swisher, MD, FACS; and Ken Y. Yoneda, MD.
The staff of Physicians' Education Resource®, LLC: Leigh Anne Bongiovanni; Ann C. Lichti, CCMEP; David Lee, PhD; and Megan O'Connell.
The following individuals have relevant financial relationships with commercial interests to disclose:
Paul Baas, MD, PhD -- Grant/Research Support: Pfizer; Consultant: Bristol-Myers Squibb, MSD, Verastem.
Paul Bunn, Jr., MD -- Grant/Research Support: Eisai; Consultant: Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Amgen, Celgene, Daiichi Sankyo, GlaxoSmithKline, Genentech/Roche, Lilly, Pfizer, Merck, Novartis.
Roy Decker, MD, PhD -- Grant/Research Support: Merck, 21st Century Oncology; Consultant: AMAG Pharmaceuticals; Stock/Shareholder: Bristol-Myers Squibb.
David R. Gandara, MD -- Research Funding: Abbott, Bristol-Myers Squibb, ImClone, Genentech, Lilly, Merck, Novartis, Pfizer; Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, sanofi-aventis, Response Genetics Inc., Synta; Non-Profits: ASCO, IASLC, ESMO, NCI, Addario Foundation.
Barbara Gitlitz, MD –Speakers' Bureau: Genentech, Eli Lilly, Pfizer.
Roy S. Herbst, MD, PhD -- Consultant: SAB, Kolltan, N-of-One, Inc., DiaTech Oncology, Quintiles Inc., Biothera.
Fred R. Hirsch, MD, PhD -- Grant/Research Support: Celgene, Genentech, Ventana, Amgen, ImClone/Lilly; Consultant: Genentech/Roche, Pfizer, Novartis, Celgene, Biodesix, Biothera, Synta.
Juliane M. Juergensmeier, PhD -- Grant/Research Support: AstraZeneca.
Karen Kelly, MD -- Grant/Research Support: Millennium, Novartis, Proacta, Eli Lilly, Synta, EMD Serono, Encore; Consultant: Boehringer Ingelheim, Genentech, Clovis Oncology.
Corey J. Langer, MD, FACP -- Grant/Research Support: Bristol-Myers Squibb, Pfizer, Lilly, Genentech, OSI (Astellas), Merck, GlaxoSmithKline, Nektar; Scientific Advisor: Bristol-Myers Squibb, ImClone, sanofi-aventis, Pfizer, Lilly, Amgen, AstraZeneca, Novartis, Genentech, Bayer/Onyx, Abraxis, Abbott, Morphotek, Biodesix, Clarient, Caris DX, Vertex, Synta, Celgene, Boehringer Ingelheim; Speakers’ Bureau: Lilly, Genentech, OSI, ImClone-BMS (all curtailed as of 12/10); DSMC: Lilly, Amgen, Synta, Agennix.
Primo Lara, Jr., MD -- Grant/Research Support: Millennium, Aragon, Janssen, Polaris, OncoGeneX, GlaxoSmithKline, Genentech; Consultant: Janssen, Clovis, Astex, USOS, Exelixis, Immunojen, Pfizer, Teva, Medivation.
Sai-Hong Ignatius Ou, MD, PhD -- Grant/Research Support: Pfizer, Roche, Astellas, Clovis, AstraZeneca; Consultant: Pfizer, Ignyta; Speakers’ Bureau: Roche, Boehringer Ingelheim, Celgene.
Vassiliki Papadimitrakopoulou, MD -- Grant/Research Support: Merck, Bayer, Celgene, Astellas, AstraZeneca, Clovis, Bristol-Myers Squibb; Consultant: Amgen, Janssen, Clovis, Genentech.
Suresh Ramalingam, MD -- Consultant: Amgen, Aveo, Ariad, Boehringer Ingelheim, Celgene, Genentech, Lilly, Novartis, Gilead.
Jonathan Riess, MD, MS -- Grant/Research Support: Millennium, Onconova, Novartis; Consultant: Genentech, Celgene.
Giorgio V. Scagliotti, MD, PhD -- Speakers’ Bureau: Eli Lilly, AstraZeneca, Roche, Pfizer, Clovis Oncology.
Anne S. Tsao, MD -- Grant/Research Support: MedImmune; Consultant: Lilly, Genentech, Boehringer Ingelheim, MedImmune, Novartis, Astellas.
Everett E. Vokes, MD -- Consultant: Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Clovis, Eisai, Merck, Synta, VentiRx.
Heather A. Wakelee, MD -- Grant/Research Support: Genentech/Roche, Lilly, Pfizer, Novartis, Exelixis, Xcovery, AstraZeneca, Clovis, Regeneron; Consultant: Peregrine.
Ignacio I. Wistuba, MD -- Grant/Research Support: Genentech, Merck, Eli Lilly, Myriad, OncoPlex; Consultant: Genentech, Roche, GlaxoSmithKline, General Electric, Pfizer, Eli Lilly, Ventana, Novartis, Boehringer Ingelheim, GeneCentric.
James CH Yang, MD, PhD -- Grant/Research Support: Boehringer Ingelheim; Consultant: Boehringer Ingelheim, AstraZeneca, Roche, Bayer, Pfizer, Novartis, Clovis, Eli Lilly, Merck Serono, Takeda.
Off-Label Disclosure and DisclaimerThis CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
PER® Practice Pulse
Lung: Practice Pattern Questions
Which of the following therapies would you most frequently recommend as first-line treatment for a patient diagnosed with NSCLC (adenocarcinoma histology with an EML4-ALK rearrangement)?
Calendar of Events
February 20, 2016
Miami Beach, FL
Feb 20, 2016
Feb 20, 2016